A Real-World study to evaluate infectious complications of Nivolumab therapy in patients with Relapsed/Refractory Hodgkin's Lymphoma
Latest Information Update: 20 Jul 2020
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 30 Aug 2019 New trial record